MX2017010157A - Compuestos con actividad anti-tumoral. - Google Patents

Compuestos con actividad anti-tumoral.

Info

Publication number
MX2017010157A
MX2017010157A MX2017010157A MX2017010157A MX2017010157A MX 2017010157 A MX2017010157 A MX 2017010157A MX 2017010157 A MX2017010157 A MX 2017010157A MX 2017010157 A MX2017010157 A MX 2017010157A MX 2017010157 A MX2017010157 A MX 2017010157A
Authority
MX
Mexico
Prior art keywords
compounds
tumoral activity
cells
formula
destroy
Prior art date
Application number
MX2017010157A
Other languages
English (en)
Inventor
Benjahad Abdellah
Moussy Alain
Chevenier Emmanuel
Picoul Willy
Pez Didier
Sandrinelli Franck
Martin Jason
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of MX2017010157A publication Critical patent/MX2017010157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a compuestos de la fórmula general (I) (Ver fórmula) en donde A representa un grupo heterociclo opcionalmente sustituido, B representa un grupo arilo o heteroarilo y en donde X, R1, R2, R3, R4 y R5 son como se definen en la descripción. Los compuestos de la fórmula (I) son útiles para destruir, inhibir o evitar el crecimiento o diseminación de células, especialmente células malignas, en tejidos circundantes implicados en una variedad de enfermedades humanas y animales.
MX2017010157A 2015-02-05 2016-02-05 Compuestos con actividad anti-tumoral. MX2017010157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154028.3A EP3053920B1 (en) 2015-02-05 2015-02-05 Compounds with anti-tumoral activity
PCT/EP2016/052523 WO2016124747A1 (en) 2015-02-05 2016-02-05 Compounds with anti-tumoral activity

Publications (1)

Publication Number Publication Date
MX2017010157A true MX2017010157A (es) 2017-12-18

Family

ID=52450012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010157A MX2017010157A (es) 2015-02-05 2016-02-05 Compuestos con actividad anti-tumoral.

Country Status (25)

Country Link
US (1) US10570122B2 (es)
EP (2) EP3053920B1 (es)
JP (1) JP6713000B2 (es)
KR (1) KR102544132B1 (es)
CN (1) CN107531685B (es)
AR (1) AR103629A1 (es)
AU (1) AU2016214283B2 (es)
BR (1) BR112017016883B1 (es)
CA (1) CA2975644A1 (es)
CY (1) CY1124948T1 (es)
DK (1) DK3253749T3 (es)
ES (2) ES2796276T3 (es)
HK (1) HK1243700A1 (es)
HR (1) HRP20220114T1 (es)
HU (1) HUE059063T2 (es)
IL (1) IL253779A0 (es)
LT (1) LT3253749T (es)
MX (1) MX2017010157A (es)
PL (1) PL3253749T3 (es)
PT (1) PT3253749T (es)
RS (1) RS62901B1 (es)
RU (1) RU2758259C2 (es)
TW (1) TWI748938B (es)
WO (1) WO2016124747A1 (es)
ZA (1) ZA201705537B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN109467531A (zh) * 2017-09-08 2019-03-15 沈阳科创化学品有限公司 一种取代吡啶二羧酸衍生物的制备方法
CN112225733B (zh) * 2020-11-25 2022-12-09 湖南科技大学 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US810665A (en) * 1905-10-10 1906-01-23 Joseph Mlada Mold for butter.
US1346834A (en) * 1918-08-17 1920-07-20 Charles E Mcmanus Resilient rod
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
EP1146875A4 (en) * 1998-12-07 2002-05-02 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
JP4216947B2 (ja) * 1999-05-18 2009-01-28 三井化学株式会社 アミン化合物
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
JP4726486B2 (ja) * 2002-08-02 2011-07-20 アブ サイエンス ２−（３−アミノアリール）アミノ−４−アリール−チアゾールおよびそれらのｃ−ｋｉｔ阻害薬としての使用法
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
CA2542909C (en) * 2003-10-23 2012-07-10 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
JP2008510766A (ja) * 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
NZ563866A (en) * 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
WO2007026251A2 (en) * 2005-07-14 2007-03-08 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
CA2617394C (en) * 2005-09-13 2014-06-03 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
ES2460918T3 (es) * 2006-03-31 2014-05-16 Novartis Ag Derivados de ácido (4-[4-[5-(amino sustituido)-piridin-2-il]fenil]-ciclohexil)-acético como inhibidores de DGAT
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
KR20090101281A (ko) * 2007-01-23 2009-09-24 팔라우 파르마 에스에이 퓨린 유도체
WO2008103500A1 (en) 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP2011527680A (ja) * 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
JP2012532912A (ja) * 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
WO2011057214A2 (en) * 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
SG182480A1 (en) * 2010-01-12 2012-08-30 Ab Science Thiazole and oxazole kinase inhibitors
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
WO2012037132A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
EP2714667B1 (en) * 2011-05-27 2020-11-25 Laxman S. DESAI Aminooxazole inhibitors of cyclin dependent kinases
US9168245B2 (en) 2011-07-27 2015-10-27 Ab Science Selective protein kinase inhibitors
KR101896035B1 (ko) * 2011-08-23 2018-09-07 덕산네오룩스 주식회사 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말
CN103436048B (zh) * 2013-08-08 2014-12-03 陕西师范大学 硫脲供体双桥链有机染料及其应用
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
WO2015144614A1 (en) * 2014-03-24 2015-10-01 Ab Science Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
EP3144307A1 (en) * 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk

Also Published As

Publication number Publication date
IL253779A0 (en) 2017-09-28
US20180079747A1 (en) 2018-03-22
BR112017016883B1 (pt) 2023-03-07
EP3253749B1 (en) 2021-12-08
ES2796276T3 (es) 2020-11-26
JP6713000B2 (ja) 2020-06-24
EP3253749A1 (en) 2017-12-13
TWI748938B (zh) 2021-12-11
JP2018504415A (ja) 2018-02-15
RU2017127484A (ru) 2019-03-05
US10570122B2 (en) 2020-02-25
PT3253749T (pt) 2022-02-03
RS62901B1 (sr) 2022-03-31
RU2758259C2 (ru) 2021-10-27
KR102544132B1 (ko) 2023-06-15
HRP20220114T1 (hr) 2022-04-15
HK1243700A1 (zh) 2018-07-20
KR20170117407A (ko) 2017-10-23
LT3253749T (lt) 2022-02-25
RU2017127484A3 (es) 2019-08-14
BR112017016883A2 (pt) 2018-03-27
EP3053920A1 (en) 2016-08-10
EP3053920B1 (en) 2020-04-08
CA2975644A1 (en) 2016-08-11
ES2905412T3 (es) 2022-04-08
CN107531685B (zh) 2021-04-23
HUE059063T2 (hu) 2022-10-28
AR103629A1 (es) 2017-05-24
WO2016124747A1 (en) 2016-08-11
CY1124948T1 (el) 2023-01-05
AU2016214283B2 (en) 2020-07-16
ZA201705537B (en) 2020-11-25
AU2016214283A1 (en) 2017-08-10
CN107531685A (zh) 2018-01-02
PL3253749T3 (pl) 2022-03-07
DK3253749T3 (da) 2022-02-28
TW201636345A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MD3500564T2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AU2015374459A8 (en) Picolinamide compounds with fungicidal activity
MX2017008439A (es) Compuestos de picolinamida con actividad fungicida.
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
EA201201648A1 (ru) Стимуляторы sgc
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
ZA201904522B (en) Heterocyclic inhibitors of mct4
PE20160200A1 (es) Inhibidores de bromodominios
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX351812B (es) Derivados de piridona.
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
MX2016010451A (es) Benzoxaboroles microbicidamente activos.
MX2015008441A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3, 4-dihidropirimidin-1 (2h)-carboxilato.
NZ726695A (en) Gls1 inhibitors for treating disease
NZ628927A (en) Compounds and methods for treating candidiasis and aspergillus infections
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Legal Events

Date Code Title Description
FG Grant or registration